John Chan, MD

TitleAssociate Clinical Professor
InstitutionUniversity of California San Francisco
DepartmentOb/Gyn, Reproductive Sciences
Address1600 Divisadero
San Francisco CA 94115
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    John K. Chan, MD, is the Director of Gynecologic Oncology and a specialist in the surgical and medical treatment of ovarian and other complex pelvic cancers at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Chan oversees the Division’s activities and development in patient care, research and education. His research focuses on developing new therapies for gynecologic cancers, including genomic therapy and targeted biologic therapies, as well as investigating the role of tumor-initiating cells in ovarian cancer. He is involved in population-based studies examining treatment and health outcome of ovarian and uterine cancer patients. Dr. Chan has also recently been appointed the principal investigator one of the largest advanced ovarian cancer clinical trials in the world, which is currently under development at the National Cancer Institute.

    Collapse Research 
    Collapse Research Activities and Funding
    Prophylactic oophorectomy: practice patterns &outcomes
    NIH/NIA R03AG032602Aug 15, 2008 - Jul 31, 2010
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Chan JK, Gardner AB, Mann AK, Kapp DS. Hospital-acquired conditions after surgery for gynecologic cancer - An analysis of 82,304 patients. Gynecol Oncol. 2018 Jul 20. PMID: 30037490.
      View in: PubMed
    2. Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clin Exp Metastasis. 2018 Jun 21. PMID: 29931499.
      View in: PubMed
    3. Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 Jun 16. PMID: 29921512.
      View in: PubMed
    4. Chan JK, Kapp DS. Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy. Gynecol Oncol. 2017 11; 147(2):237-239. PMID: 29096823.
      View in: PubMed
    5. Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, Gaillard S, Ramirez PT, Chafe W, Monk BJ, Aghajanian C. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):554-559. PMID: 28728751.
      View in: PubMed
    6. Chan JK, Java JJ, Fuh K, Monk BJ, Kapp DS, Herzog T, Bell J, Young R. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. Gynecol Oncol. 2016 Dec; 143(3):490-495. PMID: 27771168.
      View in: PubMed
    7. Chan JK, Gardner AB, Chan JE, Guan A, Alshak M, Kapp DS. The influence of age and other prognostic factors associated with survival of ovarian immature teratoma - A study of 1307 patients. Gynecol Oncol. 2016 09; 142(3):446-51. PMID: 27423379.
      View in: PubMed
    8. Chan JK, Gardner AB, Liao CI, Chan J, Guan A, Alshak M, Kapp DS. Racial disparities in presentation and survival of ovarian yolk sac cancer patients: a study of 423 women. Am J Obstet Gynecol. 2016 08; 215(2):248-9. PMID: 27156674.
      View in: PubMed
    9. Chan JK, Monk BJ. Reply to F.M. Muggia. J Clin Oncol. 2016 Mar 10; 34(8):882-3. PMID: 26834062.
      View in: PubMed
    10. Chan JK, Gardner AB, Taylor K, Thompson CA, Blansit K, Yu X, Kapp DS. Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates. Gynecol Oncol. 2015 Nov; 139(2):300-5. PMID: 26363212.
      View in: PubMed
    11. Chan JK, Gardner AB, Thompson CA, Kapp DS. The use of clinical characteristics to help prevent morcellation of leiomyosarcoma: An analysis of 491 cases. Am J Obstet Gynecol. 2015 Dec; 213(6):873-4. PMID: 26226552.
      View in: PubMed
    12. Chan JK, Gardner AB, Taylor K, Blansit K, Thompson CA, Brooks R, Yu X, Kapp DS. The centralization of robotic surgery in high-volume centers for endometrial cancer patients--a study of 6560 cases in the U.S. Gynecol Oncol. 2015 Jul; 138(1):128-32. PMID: 25933680.
      View in: PubMed
    13. Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, Kapp DS. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008 Oct 21; 99(8):1210-5. PMID: 18813312; PMCID: PMC2570503.
    14. Chan J, Fuh K, Shin J, Cheung M, Powell C, Chen LM, Kapp D, Osann K. The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? Br J Cancer. 2008 Apr 08; 98(7):1191-6. PMID: 18349835; PMCID: PMC2359639.
    15. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Kapp DS. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007 Jun 18; 96(12):1817-22. PMID: 17519907; PMCID: PMC2359970.
    John's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Related Authors
    People who share related concepts with this person.